Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

420 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Identification of fusion genes in breast cancer by paired-end RNA-sequencing.
Edgren H, Murumagi A, Kangaspeska S, Nicorici D, Hongisto V, Kleivi K, Rye IH, Nyberg S, Wolf M, Borresen-Dale AL, Kallioniemi O. Edgren H, et al. Among authors: kallioniemi o. Genome Biol. 2011;12(1):R6. doi: 10.1186/gb-2011-12-1-r6. Epub 2011 Jan 19. Genome Biol. 2011. PMID: 21247443 Free PMC article.
Integrated breast cancer genomics.
Edgren H, Kallioniemi O. Edgren H, et al. Among authors: kallioniemi o. Cancer Cell. 2006 Dec;10(6):453-4. doi: 10.1016/j.ccr.2006.11.007. Cancer Cell. 2006. PMID: 17157784 Free article.
Systematic analysis of microRNAs targeting the androgen receptor in prostate cancer cells.
Östling P, Leivonen SK, Aakula A, Kohonen P, Mäkelä R, Hagman Z, Edsjö A, Kangaspeska S, Edgren H, Nicorici D, Bjartell A, Ceder Y, Perälä M, Kallioniemi O. Östling P, et al. Among authors: kallioniemi o. Cancer Res. 2011 Mar 1;71(5):1956-67. doi: 10.1158/0008-5472.CAN-10-2421. Epub 2011 Feb 22. Cancer Res. 2011. PMID: 21343391
Drug-Sensitivity Screening and Genomic Characterization of 45 HPV-Negative Head and Neck Carcinoma Cell Lines for Novel Biomarkers of Drug Efficacy.
Lepikhova T, Karhemo PR, Louhimo R, Yadav B, Murumägi A, Kulesskiy E, Kivento M, Sihto H, Grénman R, Syrjänen SM, Kallioniemi O, Aittokallio T, Wennerberg K, Joensuu H, Monni O. Lepikhova T, et al. Among authors: kallioniemi o. Mol Cancer Ther. 2018 Sep;17(9):2060-2071. doi: 10.1158/1535-7163.MCT-17-0733. Epub 2018 Jul 3. Mol Cancer Ther. 2018. PMID: 29970484
Individualized systems medicine strategy to tailor treatments for patients with chemorefractory acute myeloid leukemia.
Pemovska T, Kontro M, Yadav B, Edgren H, Eldfors S, Szwajda A, Almusa H, Bespalov MM, Ellonen P, Elonen E, Gjertsen BT, Karjalainen R, Kulesskiy E, Lagström S, Lehto A, Lepistö M, Lundán T, Majumder MM, Marti JM, Mattila P, Murumägi A, Mustjoki S, Palva A, Parsons A, Pirttinen T, Rämet ME, Suvela M, Turunen L, Västrik I, Wolf M, Knowles J, Aittokallio T, Heckman CA, Porkka K, Kallioniemi O, Wennerberg K. Pemovska T, et al. Among authors: kallioniemi o. Cancer Discov. 2013 Dec;3(12):1416-29. doi: 10.1158/2159-8290.CD-13-0350. Epub 2013 Sep 20. Cancer Discov. 2013. PMID: 24056683
Consistency in drug response profiling.
Mpindi JP, Yadav B, Östling P, Gautam P, Malani D, Murumägi A, Hirasawa A, Kangaspeska S, Wennerberg K, Kallioniemi O, Aittokallio T. Mpindi JP, et al. Among authors: kallioniemi o. Nature. 2016 Nov 30;540(7631):E5-E6. doi: 10.1038/nature20171. Nature. 2016. PMID: 27905421 No abstract available.
420 results